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Aspergillus invasive otitis externa (IOE) is rare and often occurs in the immunocompromised hosts. An
immunocompetent case of Aspergillus IOE complicated by herpes zoster oticus is described in this report.
The patient presented with refractory otorrhea and otalgia that continued for a long time after resolution
of the herpes zoster oticus. She was successfully treated for 8 weeks with oral voriconazole. To our
knowledge, this is the ﬁrst description of an immunocompetent case of Aspergillus IOE complicated by
herpes zoster oticus.
Copyright  2011, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC.
All rights reserved.1. Introduction
Herpes zoster has been described in all age group and the life-
time risk is estimated to be 10%e20%. The incidence of herpes
zoster is about 150e300 cases per 100,000, with the incidence
dramatically increased in patients older than 60 years [1]. Herpes
zoster oticus is a type of herpes zoster that involves external ear. In
addition to causing skin lesions, it may affect the geniculate
ganglion, causing facial palsy, tinnitus, hearing loss, nausea, vom-
iting, vertigo, and nystagmus [2,3].
Although herpes zoster disrupts the integrity of the skin and
mucosa, secondary infection is rare. When this happens, the
responsible organism is often Staphylococcus aureus, b-hemolytic
Streptococcus, or Hemophilus inﬂuenzae [4e6]. Aspergillus invasive
otitis externa (IOE) complicated by herpes zoster oticus has not
been reported previously. Here, we report an immunocompetent
case of Aspergillus IOE complicated by herpes zoster oticus, who
presented with prolonged otalgia and otorrhea.2. Case report
The patient was a 50-year-old woman and a tea farmer who ran
a teamarket. Shehadbeenhealthyandnever takenanymedicineuntil
12 months ago. She presented with severe left ear pain, vertigo, andase, Department of Medicine,
g Road, Dalin, Chiayi, Taiwan.
ddhist Compassion Relief Tzu Chiheadache. She went to her local clinic, where a physical examination
showederythematous swellingandvesicles affectingher left ear canal
and pinna that were compatible with herpes zoster oticus. She was
transferred and admitted to ourhospital,where intravenous acyclovir
500 mg every 8 hours and clindamycin 600 mg every 8 hours were
administrated. Her vesicles crusted and the swelling of ear canal
subsidedgradually.After a13-dayhospitalization, shewasdischarged.
However, she was admitted 1 week later because of severe vertigo.
Physical examination showed that the shallowwounds in her left ear
canal had reached the healing stage. Brainmagnetic resonance image
revealed no organic lesions. She received symptomatic treatment and
hydrocortisone 100mg every 8 hours for 2 days. The vertigo became
milder and she was discharged. Because of itching sensations within
her left ear canal, she often used Q-tips to clean her ear.
Two months later, she began to suffer from left otalgia, otorrhea,
and hearing impairment. A physical examination revealed an ulcer
and yellowish discharge on the posterior area of her left external ear
canal. The laboratory data did not show leukocytosis or elevated
C-reactive protein. Intravenous cefazolin 1,000 mg every 8 hours and
gentamicin 80mg every 12 hourswere administratedwith curettage
of the local necrotizing tissues. A pus culture yielded coagulase-
negative Staphylococci and mold-like pathogens. Her symptoms
became milder and she was discharged. One month later, the otor-
rhea and otalgia ﬂared up again. A physical examination still showed
the presence of the same ulcerative woundwith yellowish discharge
in her left ear canal. Intravenous amoxicillin/clavulanic acid
1,200 mg every 8 hours was administrated with curettage of the
local necrotizing tissues. A wound cultured yielded a mold-like
pathogen. The otorrhea became less and she was discharged.Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
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physical examinations with normal laboratory data. Intravenous
ciproﬂoxacin 400 mg every 12 hours and gentamicin 80 mg every
12 hours were administrated with curettage of the local necrotizing
tissues. Because of lessening of the otorrhea, she was discharged.
However, the same symptoms ﬂared up again 3 months later with
the same physical examination. Intravenous ceftazidime 2 g every
12 hours and oral doxycycline 100 mg every 12 hours were
administrated with curettage of local necrotizing tissues. Her
otorrhea became less and she was discharged.
One month later, the same symptoms recurred and she was
admitted. Physical examination showed ulceration and erythema-
tous swelling with yellowish discharge on the posterior area of her
left external ear canal. Her blood cell count, erythrocyte sediment
rate, C-reactive protein, and serum electrolyte were all within
normal limits. Serum autoimmune proﬁle, such as antinuclear
antibody, rheumatoid factor, C3, C4, antineutrophil cytoplasmic
antibodies, immunoglobulin G (IgG), IgA, and IgM was normal.
A chest ﬁlm showed no speciﬁc ﬁnding. Computed tomography
showed increased soft tissue density around the left external
auditory canal close to the tympanic membrane (Fig. 1). A pus
culture yielded mold-like pathogen, which was identiﬁed as
Aspergillus nigra. Culture of the same sample for Mycobacterium
yielded nothing. Intravenous ceftazidime 2 g every 8 hours and
vancomycin 1 g every 12 hours were used with tropical oﬂoxacin
for 4 weeks. However, her otorrhea and otalgia persisted. The
antibiotic treatment was shifted to oral voriconazole 200 mg every
12 hours and intravenous clindamycin 600 mg every 8 hours. Her
otorrhea and otalgia subsided gradually. Physical examination
showed an improvement of the swelling and ulceration of left
external canal. She was discharged and maintained on oral vor-
iconazole 200 mg every 12 hours and amoxicillin 500 mg every 8
hours for 8 weeks. On follow up at 8 months, the patient was free of
symptoms.
3. Discussion
IOE is an ear infection spreading from the external auditory
canal to adjacent anatomical structures, including soft tissues,Fig. 1. The computed tomography discloses increased soft tissue density (arrow)
around left external auditory canal close to the tympanic membrane.cartilage, and bone [7]. Aspergillus is a rare cause of IOE [8]. When
Aspergillus IOE occurs, this pathogen slowly invades adjacent soft
tissues and the mastoid air cells. Most cases with Aspergillus IOE
involve persons who are immunocompromised, usually those who
have long-lasting neutropenia, who are on long-term steroid
therapy, or who have uncontrolled diabetes mellitus [9,10]. In
immunocompetent patients, diagnosis is often delayed because
Aspergillus is very rare cause of IOE, compared with, for example,
P aeruginosa [8,11]. In our case, the pus cultured yielded mold-like
pathogen at ﬁrst but it was considered to be a colonized microor-
ganism because her symptoms responded to treatment that did not
include an antifungal agents. In addition, Aspergillus IOE is very rare
in immunocompetent patients. Because of recurrent courses of her
disease, Aspergillus was ﬁnally considered to be the pathogen and
the correct treatments could be administrated. Tracing back her
whole course, we found there had been no systemic inﬂammatory
response syndromes, such as leukocytosis, fever, tachycardia, or
elevated C-reactive proteins, in this immunocompetent patient
with Aspergillus IOE. Local curettage of necrotizing tissues seems to
be able to improve otorrhea transiently in patients with Aspergillus
IOE but is impossible to eradicate pathogens completely. Even
when the patient is immunocompetent, Aspergillus still should be
considered as a possible pathogen of IOE, especially when the
clinical course is refractory or recurrent under antibiotics
treatment.
Herpes zoster oticus is characterized by the vesicles on the
antihelix and external canal after onset of the preherpetic pain.
Resolution of the inﬂammation and lesions occurs in 10e14 days.
However, the patient may experience itching during this period.
Patients are advised to avoid scratching the ear to avoid spreading
the lesions or having the wound developing a secondary infection
[12]. Aspergillus is commonly found in soil, dust, plants, and
decaying vegetable matter. Our patient was a tea farmer and
therefore it is quite possible that Aspergillus might have easily
colonized her ear via her hands during her work. The Aspergillus
may be inoculated into the unhealed wound in the external ear
canal through scratching the ear with her hands. In addition,
transient treatment with hydrocortisone for her vertigo during the
secondary admission is a possible precipitating factor that might
have assisted the colonizing Aspergillus to become invasive.
The treatment of Aspergillus IOE classically includes extensive
surgical debridement and intensive long-term antifungal therapy,
including amphotericinB and/or itraconazole. In aprevious report, 24
cases with Aspergillus IOE were reviewed [13]. The most commonly
usedantifungal agentwasamphotericinB. Thisdrug is effectivewhen
treating of Aspergillus IOE, but its substantial toxicity proﬁle must be
taken into account. The median total dose of amphotericin B
administered was 2 g (range, 0.8e2.5 g) and the patients needed
prolonged hospitalization. Two patients in that report were
successfully treated with long-term voriconazole therapy, like our
patient. Voriconazole is currently considered the ﬁrst-line thera-
peutic option for invasive aspergillosis, based on its high intrinsic
anti-Aspergillus activity and its superiority when compared with
intravenous amphotericin B in large randomized trials [14,15]. In
addition, this broad-spectrum azole distributes itself throughout the
body, including soft tissue and bone, where good diffusion has been
recently documented [16]. Because of the drug havingmore than 90%
oral bioavailability, patients treated with voriconazole do not need
prolongedhospitalization [17]. Thus, voriconazolemaybe considered
an attractive ﬁrst-line therapeutic option for Aspergillus IOE.
In conclusion, we presented an immunocompetent case who
suffered from Aspergillus IOE complicated by herpes zoster oticus.
We successfully treated the patient using voriconazole without
surgical debridement. Aspergillus should be considered as a path-
ogen for refractory IOE, even in an immunocompetent patient.
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